Titan Pharmaceuticals, Inc.

281 articles about Titan Pharmaceuticals, Inc.

• Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference

  12/3/2019

  The presentation will be broadcast live and archived on Titan's website at www.titanpharm.com/news/events.

• Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results

  11/14/2019

  In July 2019, Titan announced a specialty product distribution agreement for Probuphine® (buprenorphine) implants with CVS Caremark, a subsidiary of CVS Health.

• Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow

  11/7/2019

  Titan Pharmaceuticals, Inc. will announce its third quarter 2019 financial results after market close on Thursday, November 14, 2019. Following the release, Titan management will host a conference call at 4:30 p.m. EST / 1:30 p.m. PST to review the financial results and discuss business developments in the period.

• Titan Pharmaceuticals To Present Two Posters On Probuphine® At The 10th American Conference On Pharmacometrics

  10/22/2019

  Titan Pharmaceuticals, Inc. announced that it has two poster presentations on Probuphine implant, Titan's novel 6-month maintenance treatment for Opioid Use Disorder in eligible patients, at the 10th American Conference on Pharmacometrics taking place on October 20-23, 2019 in Orlando, FL..

• Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering

  10/16/2019

  Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be $9.0 million.

• Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

  10/1/2019

  Titan Pharmaceuticals, Inc. and Crossroads of Southern Nevada rehabilitation facility announced that Crossroads has healthcare providers who are specially trained in the insertion and removal of Probuphine® implants, and will now offer Probuphine for use in eligible patients with Opioid Use Disorder.

• Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results

  8/14/2019

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the second quarter ended June 30, 2019 and provided an update on its business.

• Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow

  8/9/2019

  Titan Pharmaceuticals, Inc. will announce its second quarter 2019 financial results after market close on Wednesday, August 14, 2019.

• Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering

  8/7/2019

  The combined purchase price for one share of common stock and each warrant will be $0.75.

• Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark

  7/9/2019

  Titan Pharmaceuticals, Inc. announced that it has executed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan's novel maintenance treatment for Opioid Use Disorder in eligible patients.

• Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine

  6/26/2019

  Probuphine will be marketed in the European Union under the brand name "Sixmo"

• Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®

  6/4/2019

  Titan Pharmaceuticals, Inc. announced that it has executed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine implant, Titan's novel maintenance treatment for Opioid Use Disorder in eligible patients.

• Titan Pharmaceuticals Reports First Quarter 2019 Financial Results

  5/15/2019

  Titan Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019 and provided an update on its business.

• Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

  5/13/2019

  Titan Pharmaceuticals, Inc. announced that it has executed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding access to treatment with Probuphine implant, Titan's novel maintenance treatment for Opioid Use Disorder in eligible patients.

• Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow

  5/9/2019

  Titan Pharmaceuticals, Inc. will announce its first quarter 2019 financial results after market close on Wednesday, May 15, 2019.

• Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®

  4/29/2019

  Probuphine to be marketed in the European Union under the brand name "Sixmo"

• Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

  4/1/2019

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on its business.

• Titan Pharmaceuticals Partners With AppianRx To Provide Comprehensive Probuphine® Patient Support Services

  3/28/2019

  Titan Pharmaceuticals, Inc. announced that it has executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Probuphine implant, Titan's unique six-month maintenance treatment for opioid use disorder in eligible patients.

• Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019

  3/26/2019

  Management Team to Host Conference Call on April 2, 2019 at 8:30 a.m. ET / 5:30 a.m. PT

• Titan Pharmaceuticals Partners With AllianceRx Walgreens Prime Specialty Pharmacy To Expand Patient Access To Probuphine®

  2/25/2019

  Titan Pharmaceuticals, Inc. announced the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine implant, Titan's unique six-month maintenance treatment for opioid use disorder in eligible patients.